2023 Fiscal Year Research-status Report
The research of targeting tumor-associated dendritic cells, a new therapy strategy by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses
| Project/Area Number |
23K14668
|
|---|
| Research Institution | National Center for Child Health and Development |
|---|
Principal Investigator |
Hu Xin 国立研究開発法人国立成育医療研究センター, 移植免疫研究室, (非)研究員 (40868965)
|
|---|
| Project Period (FY) |
2023-04-01 – 2025-03-31
|
| Keywords | Combined phospholipids / TADC / TIL / TME |
|---|
| Outline of Annual Research Achievements |
1,Administering phospholipids significantly inhibited tumor growth in B6 mice with established subcutaneous B16F10 tumors and in BalB/c mice with established subcutaneous C26 tumors. 2,Our research revealed that phospholipids markedly boost the expression of CD86 and MHCII,and the cytokine secretion . 3,TADCs expression Tim-4
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
1, We cirform the anti-tumor effect of Phospholipids in different tumor model.
2, We cirform the phospholipids enhance TADCs anti-tumor effect in vivo and in vitro
3, We cirform the mechanism for phospholipids promoting TADCs anti-tumor effect
|
| Strategy for Future Research Activity |
Next, we will use the exploration of mechanisms as our research.
|
